NCT01118689View on ClinicalTrials.gov

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2013

Conditions
Relapsed Multiple MyelomaRefractory Multiple MyelomaWaldenstrom Macroglobulinemia
Interventions
DRUG

MLN0128

MLN0128 administered orally once daily for 28 days

Trial Locations (6)

37203

Nashville

63110

St Louis

80218

Denver

94143

San Francisco

02115

Boston

07601

Hackensack

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY